Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Optimed Research Ltd

Neither a doctor nor a teaching hospital

Research payments

$2,576,091

1,082 payments

Through program year 2025, Optimed Research Ltd is reported as receiving $2,576,091 in research payments, across 1,082 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $191,786 75
2024 Research $222,067 146
2023 Research $321,384 126
2022 Research $346,514 163
2021 Research $507,198 453
2020 Research $660,108 80
2019 Research $327,034 39

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $601,059 155 payments
  2. Kedrion S.p.A. $487,437 37 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $486,394 569 payments
  4. Genzyme Corporation $181,396 25 payments
  5. Regeneron Pharmaceuticals, Inc. $162,398 57 payments
  6. Octapharma USA, Inc. $132,914 3 payments
  7. Pfizer Inc. $117,731 45 payments
  8. Eli Lilly and Company $102,642 10 payments
  9. Shire North American Group Inc $87,874 16 payments
  10. Incyte Corporation $61,517 122 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients $487,437 37 payments
  2. A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-Histaminergic Angioedema With Normal C1-Inhibitor (C1-Inh) and Acquired Angioedema (Aae) Due to C1-Inh Deficiency $296,444 467 payments
  3. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) $177,261 41 payments
  4. An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-Histaminergic Angioedema With Normal C1-Inhibitor (C1-Inh) $128,595 55 payments
  5. Cutaquig Registry $120,000 1 payment
  6. Help Study Extensiontm An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Dx-2930 for Prevention Against Acute Attacks of Hereditary Angioedema Hae $87,874 16 payments
  7. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $87,367 31 payments
  8. A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 $81,373 18 payments
  9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of Ly3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines $77,200 5 payments
  10. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee $72,779 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record